Results 111 to 120 of about 20,409 (197)

Machine learning model for HBsAg seroclearance after 48-week pegylated interferon therapy in inactive HBsAg carriers: a retrospective study. [PDF]

Virol J
Dong J, Ren S, Zhao J, Wu P, Yu H, Xie Y, Fu J, Mao X, Gao Z, Lin B, Ruan Q, Jiang Y, Xue X, Zhu Y, Zhao H, Cao H, Chen X, Zheng S.   +17 more
europepmc   +1 more source

Pegylated Interferon-α-Induced Functional Cure for Special Populations with Chronic Hepatitis B Virus Infection: Current Trends, Challenges and Prospection. [PDF]

Drug Des Devel Ther
Zhang Y, Li Y, Lian JQ, Kang W.
europepmc   +1 more source

Frequency, Severity and Impact of Pegylated Interferon Alpha-Associated Flares in Hepatitis D Infection. [PDF]

J Viral Hepat
Hardtke S, Yurdaydin C, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Port K, Manns MP, Cornberg M, Kahlhöfer J, Wedemeyer H.   +15 more
europepmc   +1 more source

[Expert recommendations on the management of adverse reactions in pegylated interferon alpha therapy for chronic hepatitis B]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Expert Group on the Management of Adverse Reactions in Pegylated Interferon Alpha Therapy for Chronic Hepatitis B.
europepmc   +1 more source

Pegylated interferon-α-2b add-on therapy to renal function for chronic hepatitis B patients who were treated with tenofovir disoproxil fumarate: a retrospective real-world study. [PDF]

Virol J
Wang TB, Li AH, Zhuo Y, Wu HJ, Yue MQ, Wang YP, Wang XH.   +6 more
europepmc   +1 more source

Incidence and predictors of HBsAg loss following addition of pegylated interferon Alfa-2b in chronic hepatitis B patients suppressed by nucleos(t)ide analogues: a multicenter, prospective, cohort study. [PDF]

Virol J
Zhao J, Bian D, Xie D, Lv J, Lin L, Chen X, Zhang L, Feng B, Xu X, Lu F, Zheng S.   +10 more
europepmc   +1 more source

Adding pegylated interferon-α to nucleos(t)ide analogs improves HBsAg clearance in chronic hepatitis B with low-level viremia. [PDF]

Front Med (Lausanne)
Wang L, Lu J, Liu D, Ren S, Chen X, Hu Z, Zheng S.   +6 more
europepmc   +1 more source

Organizing pneumonia in a patient following treatment of chronic hepatitis B with pegylated interferon alfa-2b: A case report. [PDF]

IDCases
Tian B, Wang P, Shan C, Gao C, Zhang Q.
europepmc   +1 more source

Correction: Efficacy and safety of pegylated interferon in the treatment of JAK2^V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study. [PDF]

Front Oncol
Chang L, Li WX, Cai H, Li J, Duan MH.
europepmc   +1 more source

The safety, tolerability, pharmacokinetics, and pharmacodynamics of nebulized pegylated interferon α-2b in healthy adults: a randomized phase 1 trial. [PDF]

BMC Pharmacol Toxicol
Huang W, Kang Y, Zhao Y, Yang J, Dai C, Wu W, Xu J, Jin W, Wu X, Zhou Q.   +9 more
europepmc   +1 more source